Antibodies attacking virus cell (illustration)

Image source: Shutterstock/Christoph Burgstedt

News • SARS-CoV-2 neutralising antibodies

Covid-19 immunity may last from days to decades

Scientists from Singapore found that antibodies against SARS-CoV-2 wane at different rates, lasting for mere days in some individuals, while remaining present in others for decades.

The study, published in The Lancet Microbe, shows that the severity of the infection could be a deciding factor in having longer-lasting antibodies. Individuals with low levels of neutralising antibodies may still be protected from Covid-19 if they have a robust T-cell immunity.

The team followed 164 Covid-19 patients in Singapore for six to nine months, analysing their blood for neutralising antibodies against SARS-CoV-2, T cells and immune system signalling molecules. They then used this data to establish a machine learning algorithm to predict the trajectories of peoples’ neutralising antibodies over time. "The key message from this study is that the longevity of functional neutralising antibodies against SARS-CoV-2 can vary greatly and it is important to monitor this at an individual level. This work may have implications for immunity longevity after vaccination, which will be part of our follow-up studies,” said Professor Wang Linfa, from Duke-NUS’ Emerging Infectious Diseases (EID) Programme, a corresponding author of the study.

This study reminds us that we all react differently to infection and that various people mount different protective immune responses. Understanding the basis of these differences will help build better vaccines

Laurent Renia

The team was able to categorise people into five groups depending on how long their antibodies lasted. The first group, who never developed detectable neutralising antibodies also called the ‘negative’ group, comprised 11.6% of the patients in the study. The ‘rapid waning’ group (26.8%) had varying early levels of antibodies that waned quickly. The ‘slow waning’ group (29%) tested mostly positive for antibodies at six months. The ‘persistent’ group (31.7%) showed little change in their antibody levels up to 180 days and, finally, the ‘delayed response’ group (1.8%) showed a marked rise in neutralising antibodies during late convalescence.

While this study focused on determining the levels of neutralising antibodies, which are part of the body’s comprehensive immune defence system, the other important aspect of an effective immune defence is T-cell immunity. The study found that the patients tested, including those from the ‘negative group’, displayed sustained T-cell immunity six months after initial infection. This shows that individuals may still be protected if they have a robust T-cell immunity when the neutralising antibody level is low. “Our study examines neutralising antibodies which are important in protection from Covid-19. We found that antibodies against SARS-CoV-2 wane in different people at different rates. This emphasises the importance of public health and social measures in ongoing pandemic outbreak response. However, the presence of T-cell immunity provides hope of longer-term protection which will require more studies and time for epidemiological and clinical evidence to confirm,” said Associate Professor David Lye, Director, Infectious Disease Research and Training Office, National Centre for Infectious Diseases (NCID), who is also a corresponding author of the study. “This study reminds us that we all react differently to infection and that various people mount different protective immune responses. Understanding the basis of these differences will help build better vaccines,” added Professor Laurent Renia, Executive Director, Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs.

The findings are important as policy makers design vaccination programmes and pandemic exit strategies. The rate of antibody waning suggests re-infection may occur in subsequent waves of infection. Also, if immunity provided via vaccinations wanes like naturally-produced antibodies, then annual vaccine administration could be necessary to prevent future outbreaks of Covid-19. Further research will be needed to clarify this as vaccine programmes are rolled out.

Source: Duke-NUS; National University of Singapore


Read all latest stories

Related articles


News • T-cell activator shows promise

"CoVac-1": Coronavirus protection for immunocompromised patients

Patients with immunodeficiency cannot benefit from conventional Covid-19 vaccines and still at risk from infection. A promising new approach now brings hope for this patient group.


News • Infection in vaccinated patients

How coronavirus variant Omicron BA.1 remodels immune memory

Researchers in France identified changes to the immune memory after infection with the Omicron BA.1 variant in thrice-vaccinated patients. The remodeling actually works to the patients' benefit.


News • Blood cancer research

Covid-19 booster vaccine strengthens immunity in lymphoma patients

Research by the University of Southampton has shown that repeated Covid-19 vaccination increases the ability of lymphoma patients to prevent infection from the virus, particularly after four doses.

Related products

Beckman Coulter – Access Procalcitonin (PCT)


Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Fujifilm Wako – μTASWako i30


Fujifilm Wako – μTASWako i30

FUJIFILM Wako Chemicals Europe GmbH
Mindray – CL-1000i/1200i Chemiluminescence Immunoassay System


Mindray – CL-1000i/1200i Chemiluminescence Immunoassay System

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Subscribe to Newsletter